Our Pipeline
We are developing an innovative cell therapy pipeline with the potential to redefine standards of care across a range of conditions where there is an urgent medical need. We are applying our proprietary CD34+ cell technology to potentially treat a number of conditions caused by underlying ischemic injury, including but not limited to, Coronary Microvascular Dysfunction (CMD), Critical Limb Ischemia (CLI), No-Option Refractory Disabling Angina (NORDA) and Diabetic Kidney Disease (DKD). These indications represent major areas of clinical need, as well as substantial commercial opportunities. Explore our pipeline below for information on our clinical development candidates and ongoing clinical trials.
| Program | Clinical Status | Pre Clinical | Phase 1 | Phase 2 | Phase 3 | Commercial |
|---|---|---|---|---|---|---|
CLBS16 | Pre Clinical | Phase 1 | Phase 2 | Phase 3 | Commercial | |
HONEDRA® (CLBS12) SAKIGAKE DESIGNATED | Pre Clinical | Phase 1 | Phase 2 | Phase 3 | Commercial | |
CLBS201 | Phase 2 (USA; Clinical Initiation Pending) | Pre Clinical | Phase 1 | Phase 2 | Phase 3 | Commercial |
CLBS14 (OLOGO™ in the U.S.) RMAT Designated | Phase 3 (USA; Initiation pending) | Pre Clinical | Phase 1 | Phase 2 | Phase 3 | Commercial |
